tiprankstipranks
Analyst Profile
Followed by 347 other investors
.
Sumant Kulkarni

Sumant Kulkarni

Canaccord Genuity
Wall Street Analyst
Ranked #1,306 out of 8,040 Analysts on TipRanks (#2,181 out of 21,629 overall experts)

Success Rate

43%
118 out of 273 Profitable Transactions

Average Return

8.20%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Sumant Kulkarni's ratings since 2013 and opened each position for the duration of 1 Year:
43.22% of your transactions would have been profitable with an average return of 8.2%

Stock Rating Distribution

396Ratings
87.37% Buy
10.10% Hold
2.53% Sell
Distribution of Sumant Kulkarni's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Bioxcel Therapeutics
(BTAI)
Rating Type:Buy
Dates:Oct 04, 2019 - Oct 04, 2020
Gain:614.20%
The most profitable rating made by Sumant Kulkarni

Sumant Kulkarni's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
MNTA
Momenta Pharma
Mar 19, 2013
Sell
Downgraded
0%
-17.00%
1
Otonomy
Dec 19, 2014
Sell
Downgraded
$31.00
(7280.95% Upside)
100%
+53.85%
2
Bausch Health Companies
Dec 18, 2015
Buy
Reiterated
$140.00
(2468.81% Upside)
0%
-83.88%
7
SGNT
Sagent Pharm
May 09, 2016
Hold
Reiterated
0.00%
2
OREXQ
Orexigen
May 11, 2016
Sell
Reiterated
100%
+16.50%
1
CYNA
Cynapsus Therapeutics
May 12, 2016
Buy
Assigned
100%
+238.70%
1
Perrigo Company
Jun 14, 2016
Sell
Reiterated
$109.00
(168.34% Upside)
100%
+31.95%
2
AKRXQ
Akorn
Nov 07, 2016
Sell
Downgraded
67%
+37.43%
3
Amneal Pharmaceuticals
Nov 07, 2016
Sell
Reiterated
$19.00
(601.11% Upside)
33%
-40.27%
4
Viatris
Nov 09, 2016
Buy
Reiterated
$53.00
(401.42% Upside)
14%
-6.84%
8
List of latest recommendations made by Sumant Kulkarni. Click to expand and see Sumant Kulkarni's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More